CRL

In the past six months, Charles River Laboratories International, Inc. (CRL) stock has experienced a significant upward trend, increasing by 71.91%, and by 75.32% over the past year. Key events impacting CRL's stock price and business from approximately April 2026 to October 2026 include the Q2 2026 earnings report on August 5, 2026, where the company exceeded analyst expectations with $1.00 billion in revenue and $3.02 non-GAAP earnings per share, leading to increased 2026 guidance due to improving demand in the Discovery and Safety Assessment segment and strong Manufacturing segment performance. Strategic divestitures of certain European Discovery Services sites and its CDMO and Cell Solutions businesses were completed in May 2026 to refine its portfolio. The company also engaged in strategic collaborations and partnerships, joining Eli Lilly's TuneLab AI/ML platform, collaborating with Arovella Therapeutics for NGS services, partnering with Medigen Vaccine Biologics Corp. for a virus seed bank, and partnering with Autolomous to transform laboratory execution systems. Product and technology advancements included the introduction of an enhanced digital pathology solution, modernization of Endosafe® Endotoxin Testing Cartridge Manufacturing, and the launch of Apollo Orchestrate. Additionally, in October 2025, the Board of Directors approved a new $1.0 billion stock repurchase authorization.